Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.
Completed
- Conditions
- ContraceptionFemale ContraceptionFertility Control
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2016-07-19
- Target Recruit Count
- 440
- Registration Number
- NCT00511784
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder
Phase 3
Completed
- Conditions
- Bipolar Disorder
- Interventions
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2015-04-15
- Target Recruit Count
- 768
- Registration Number
- NCT00490971
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
Phase 3
Completed
- Conditions
- PainOsteoarthritisLow Back Pain
- Interventions
- First Posted Date
- 2007-06-18
- Last Posted Date
- 2014-05-09
- Target Recruit Count
- 1166
- Registration Number
- NCT00487435
A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2013-07-19
- Target Recruit Count
- 395
- Registration Number
- NCT00455520
An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis
Phase 2
Terminated
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: PlaceboDrug: JNJ-26113100 (250 mg) twice dailyDrug: JNJ-26113100 (100 mg) once dailyDrug: JNJ-26113100 (50 mg) once dailyDrug: JNJ-26113100 (100 mg) twice daily
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2014-03-12
- Target Recruit Count
- 84
- Registration Number
- NCT00455429
A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain
Phase 3
Completed
- Conditions
- Low Back Pain
- Interventions
- First Posted Date
- 2007-03-20
- Last Posted Date
- 2012-04-30
- Target Recruit Count
- 981
- Registration Number
- NCT00449176
A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: Epoetin alfa 3 times weekly /once weeklyDrug: Epoetin alfa once weeklyDrug: Epoetin alfa once every two weeks
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2014-05-07
- Target Recruit Count
- 375
- Registration Number
- NCT00440557
PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2014-04-21
- Target Recruit Count
- 430
- Registration Number
- NCT00440466
Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: RWJ-445380 100 mgDrug: RWJ-445380 200 mgDrug: RWJ-445380 300 mgDrug: Placebo
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2014-05-21
- Target Recruit Count
- 259
- Registration Number
- NCT00425321
© Copyright 2025. All Rights Reserved by MedPath